Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑001 for Relapsed Multiple Myeloma
Easton Pharmaceutical Co., Ltd. (SHA: 688513) announced that the first subject has been dosed in...
Easton Pharmaceutical
Kexing Biopharm & Easton Biopharma Sign Exclusive Overseas Licensing Deal for Apalutamide
Kexing Biopharm (SHA: 688136) today announced a strategic cooperation agreement with Chengdu Easton Biopharmaceuticals Co.,...
Easton Pharma’s Oxazepam Receives NMPA Approval and Partners with Nhwa
Chengdu-based Easton Pharmaceutical Co., Ltd. (SHA: 688513) announced that its oxazepam has received marketing approval...
Easton Pharma’s EP-9001A Shows Promising Results in Phase Ib for Bone Metastasis Cancer Pain
Chengdu-based Easton Pharmaceutical Co., Ltd (SHA: 688513) has announced preliminary statistical analysis results from the...
Easton Pharmaceutical Secures NMPA Approval for Generic Jakavi and Urocit-K
Chengdu-based Easton Pharmaceutical Co., Ltd (SHA: 688513) has announced that it has received separate marketing...
Easton Pharmaceutical Receives NMPA Approval for Generic Oxcarbazepine
Easton Pharmaceutical Co., Ltd (SHA: 688513), based in Chengdu, has announced that it has received...
Easton Pharmaceutical Gets NMPA Nod for Generic Version of Merck KGaA’s Concor
Easton Pharmaceutical Co., Ltd (SHA: 688513), based in Chengdu, has announced that it has received...
Easton Pharmaceutical Receives FDA Approval for Generic Nalmefene
Chengdu-based Easton Pharmaceutical Co., Ltd (SHA: 688513) has announced receiving Abbreviated New Drug Application (ANDA)...